GC Medical Science Corporation (KOSDAQ:142280)

South Korea · Delayed Price · Currency is KRW

3,000.00

+10.00 (0.33%)

At close: Jul 1, 2026

-25.65% (1Y)

Market Cap	65.01B -30.2%
Revenue (ttm)	105.48B -1.1%
Net Income	4.47B +171.8%
EPS	172.50 +465.2%
Shares Out	21.74M
PE Ratio	17.33
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	170,483
Open	3,015.00
Previous Close	2,990.00
Day's Range	2,900.00 - 3,100.00
52-Week Range	2,770.00 - 6,660.00
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About GC Medical Science

GC Medical Science Corporation operates as a diagnostic medical device company in the vitro diagnostic industry in South Korea and internationally. The company’s products include human healthcare products for the diagnosis of diabetes, non-communicable diseases, respiratory diseases, and vector borne diseases. It offers CERA-CHEK 1Code and CERA-CHEK 1070 for diabetes; GREENCARE A1c for HbA1c, CERA-CHEK 3 in 1 GHL for multi-diagnosis; CERA-CHEK Lactate; GREENCARE Hb and CERA-CHEK Hb Plus for haemoglobin; and GCare Lipid and GCare Lipid Printer f... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances

Founded 1972

Employees 117

Stock Exchange KOSDAQ

Ticker Symbol 142280

Full Company Profile

Financial Performance

In 2025, GC Medical Science's revenue was 108.41 billion, an increase of 4.39% compared to the previous year's 103.85 billion. Earnings were 3.67 billion, an increase of 2.38%.

Financial Statements